349593 RESULTS
COMMENT It is exciting to see that the clinical data generated on Trontinemab seems to hold together with a larger number of patients. The drop in amyloid burden is both fast and deep, which might be important for a clinical response. Also, interesting to see tha
JOB 2025-04-26 Employer Aarhus University Description Want to uncover microglia states in Alzheimer's disease? Aarhus is hiring a two-year postdoc (start: August 2025) to work with transgenic mouse models, neuroinflammation, and in vivo techniques. https://au.caree
, Australia
COMMENT This very interesting paper describes a potentially important therapeutic strategy for delivering molecules into the brain for long-term expression. If isogenic cells are used for transplantation, this method may even offer advantages over viral delivery.
COMMENT This paper takes many important steps forward in demonstrating the great potential of microglia adoptive transfer for the treatment of AD. Successes in fibrosis and autoimmunity highlight the growing application of immune cell therapies outside of oncolog
RESEARCH NEWS 2025-04-25 Research News The blood-brain barrier border protects the brain by regulating the flow of molecules, peptides, and cells, but it also keeps out many therapeutics. Now, researchers have harnessed the power of a resident drug courier, i.e., microglia. Mathe
COMMENT The most significant component of this paper lies in the novelty of using iPSC-derived microglia as a delivery system, and that this approach is able to change the course of Alzheimer’s disease pathology. Also very interesting is that—as cleverly presente
COMMENT This proof-of-concept study brings forward several important findings. Leveraging microglia—the brain’s primary immune cells, which are typically present at the scene of any pathology—as vehicles for therapeutic delivery introduces novelty into the field
University of Victoria
Canada
GRANT Friday, April 25, 2025- 4:15pm The Alzheimer’s Drug Discovery Foundation (ADDF) and the Brain Health Medicines Centers of the Harrington Discovery Institute The award typically entails up to $600,000 over 2 years. Letter of Intent: June 2, 2025, 5:00 PM E
GRANT Friday, April 25, 2025- 4:00pm The Alzheimer’s Drug Discovery Foundation (ADDF) and The Association for Frontotemporal Degeneration (AFTD) Average Award $300,000-$350,000 based on stage and scope of research. Slightly higher budgets can be considered. One
COMMENT This is a fantastic, highly important paper. Delivering biologics to the brain for therapeutic applications is notoriously difficult, often requiring intrathecal delivery of gene therapies or complex engineering of blood-brain barrier shuttles. The approa
PAPER Petit A, Barelli H, Morain P, Checler F
CONFERENCE COVERAGE 2025-04-25 Conference Coverage Talk about a closely watched study. Conference after conference, Roche scientists running the ongoing Brain Shuttle AD trial of trontinemab are dispensing morsels of news from sequential interim analyses—and they are filling large aud
CONFERENCE 2025-06-04 00:00:00-2025-06-04 00:00:00 New York City, New York and Online 04 June 2025 View Conference Website 0
